Leerink Partners analyst Marc Goodman maintains $Biogen (BIIB.US)$ with a buy rating, and adjusts the target price from $310 to $290.
According to TipRanks data, the analyst has a success rate of 48.6% and a total average return of 6.6% over the past year.
Furthermore, according to the comprehensive report, the opinions of $Biogen (BIIB.US)$'s main analysts recently are as follows:
The company's product launches continue to face challenges amidst intensifying competition, with significant pipeline catalysts anticipated to emerge in 2026 and beyond.
The launch of Leqembi has not met initial expectations, and there appears to be limited opportunities for new developments in the company's pipeline over the coming year. There was an underestimation of the initial challenges related to reimbursement and logistics for Leqembi. The perspective for Biogen now involves a balanced risk/reward scenario and a cautious forecast for lecanemab.
Biogen's third-quarter financial performance was noted to be robust, with total revenues surpassing expectations and adjusted earnings per share also beating consensus estimates. The company's sales of Leqembi are seen as outperforming, indicating vigorous momentum in the development of its infrastructure. It is expected that the intravenous maintenance and subcutaneous formulations will greatly enhance adoption rates by 2025.
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
